Patent ID: 8026096

Claim:
A method for producing a substantially pure, recombinant, glycosylated erythropoietin (EPO) that has in vivo activity, including stimulating erythropoiesis, comprising: a) infecting Spodoptera frugiperda insect cells that grow in serum-free media with a baculovirus expression system comprising a recombinant baculovirus that comprises DNA coding for EPO such that the recombinant EPO is expressed; b) culturing the infected insect Spodoptera frugiperda cells in serum-free media; and c) purifying the recombinant EPO 10 95% or greater purity, whereby the substantially pure, recombinant, glycosylated EPO that has in vivo activity of between 200,000 U/mg protein and 500,000 U/ mg protein, including stimulating erythropoiesis, is produced.